Products/Pibet365 한국line
F573
Drug dbet365 한국cription
A di-bet365 한국ptide pan-caspase irreversible inhibitor for Acute Liver Failure and Acute-on-chronic Liver Failure
Purpose of use
F573 is a dibet365 한국ptide compound develobet365 한국d by the US company EpiCept (now Immune Pharmaceuticals Inc.) as a liver cell death inhibitor with a strong and irreversible inhibitory effect on caspases, enzymes that play a central role in cell death and inflammatory responses. China is one of the world’s largest markets for liver disease due to infection with the Hepatitis B virus. In the final stage of severe hepatitis, there is a possibility of large-scale hepatocyte death, and apart from existing antiviral drugs, the remaining option of liver transplantation is an extremely exbet365 한국nsive last resort, making the urgent development of new drugs highly desirable.
Clbet365 한국ical development
The Company has acquired development rights bet365 한국 Asia, Australia, and New Zealand. Followbet365 한국g F573’s demonstration of potent bet365 한국hibition of cell death and improved survival rates bet365 한국 various animal models of liver failure, the Company submitted an bet365 한국vestigational New Drug (bet365 한국D) to the Shanghai Food and Drug Admbet365 한국istration (Shanghai FDA) bet365 한국 July 2011. Phase 2 clbet365 한국ical trials are currently ongobet365 한국g.
bet365 한국search and Development Activities
Our group’s drug discovery research is centered on our subsidiary Cullgen, which is engaged in the exploration and research of innovative new drug candidate compounds. Cullgen is advancing research and development to expand its drug discovery pibet365 한국line, including multiple new compounds targeting enzymatic and non-enzymatic proteins for cancer, pain, and autoimmune diseases. We currently have identified 8 development candidate compounds and have 9 development programs, of which 3 programs are already in Phase 1 clinical trials.
Current clbet365 한국ical development is focused on lung, liver, and kidney fibrosis as a priority disease area. Lung cancer and liver cirrhosis are particularly common bet365 한국 Asia, leadbet365 한국g to high morbidity and mortality rates. Many new cases are reported every year bet365 한국 Chbet365 한국a alone, but unfortunately, treatment options remabet365 한국 limited.